...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Experimental and therapeutic medicine >Combined IFN-alpha and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus
【24h】

Combined IFN-alpha and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus

机译：联合应用IFN-α和5-FU治疗肝细胞癌合并门静脉瘤血栓的术后辅助治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The efficacy of combination therapy with subcutaneous interferon (IFN)-alpha and intra-arterial 5-fluorouracil (5-FU) as a postoperative adjuyant for resectable advanced hepatocellular carcinoma (HCC) invading the major branches of the portal vein (PVTT) was examined. The prognosis of HCC with PVTT (Vp3 or 4) is extremely poor. Recently, we reported the possibility of combination therapy with IFN-alpha and intra-arterial 5-FU for intractable HCC with PVTT as a postoperative, adjuvant and this is the second report. Patients with HCC with PVTT were included (n=50). Thirty consecutive patients with HCC and PVTT were treated with 3 cycles of a combination therapy consisting of arterial 5-FU infusion (300 mg/mm(3)/day, 5 days/week, for the initial 2 weeks) and IFN subcutaneous injection (5 MIU, 3 times/week,4 weeks) as a postoperative adjuvant following hepatic resection; another 20 patients receiving no IFN/5-FU chemotherapy acted as controls. Results for the IFN/5-FU adjuvant treatment group were as follows: disease-free survival (n=9, 15-109 months), survival with recurrence (n=6, 30-92 months), cancer death (n=9, 14-60 months), death from other causes but no recurrence (n=5, 13-87 months) and death from other causes with recurrence (n=1, 22 months). The I-year survival rate was 100% in patients treated with IFN/5-FU, and 30%,in those without IFN/5-FU as historical controls (n=20). There was a significant difference in disease-free and overall survival rates between the two groups (P<0.0001). In conclusion, IFN/5-FU combination therapy may be a very promising postoperative adjuvant treatment for HCC with Pyrr.
机译：研究了皮下干扰素（IFN）-α和动脉内5-氟尿嘧啶（5-FU）联合手术治疗可切除的晚期肝细胞癌（HCC）侵犯门静脉主要分支（PVTT）的术后疗效。 PVTT（Vp3或4）对HCC的预后极差。最近，我们报道了将IFN-α和动脉内5-FU联合治疗顽固性肝癌的可能性，PVTT作为术后辅助药物，这是第二份报告。纳入了PVTT肝癌患者（n = 50）。连续30例HCC和PVTT患者接受了3个周期的联合疗法治疗，包括动脉5-FU输注（300 mg / mm（3）/天，最初2周为5天/周，每天2天）和IFN皮下注射（ 5例MIU，每周3次，共4周）作为肝切除术后的辅助治疗;另外20例未接受IFN / 5-FU化疗的患者作为对照。 IFN / 5-FU辅助治疗组的结果如下：无病生存（n = 9，15-109个月），复发生存（n = 6，30-92个月），癌症死亡（n = 9） （14-60个月），其他原因导致的死亡但无复发（n = 5、13-87个月）以及其他原因导致的死亡并复发（n = 1、22个月）。使用IFN / 5-FU治疗的患者的I年生存率分别为100％和30％（未使用IFN / 5-FU作为历史对照的患者）（n = 20）。两组的无病生存率和总生存率存在显着差异（P <0.0001）。总之，IFN / 5-FU联合治疗可能是Pyrr对HCC的非常有希望的术后辅助治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号